A longtime presence in the Alpine, New Jersey, community, John Klein guides the pharmaceutical company Cambridge Therapeutics as chairman. In addition to his endeavors with Cambridge Therapeutics, John Klein established Bilogix, an Alpine, New Jersey, consulting firm that will provide enterprise performance management (EPM) deliverables to companies in NJ and across the United States.
EPM is a broad system that involves coordinated strategic approaches to defining operational targets and enhancing one’s bottom line. A commonality among all EPM pathways is establishing an analytical, predictive framework for defining areas that are in need of improvement.
Using an overarching six sigma system of eliminating process waste and ensuring deliverables that meet customer needs, EPM applications employ a key performance indicators methodology for quantifying value drivers. The goal of employing this methodology is to align complex operations across divisions in ways that enable transformative, milestone-defined change. This change provides companies with the ability to pivot and effectively adapt to shifting technologies, markets, and required workforce skills.
The chairman of Cambridge Therapeutics, John Klein is a pharmaceutical industry executive whose newest venture is the Alpine, NJ, based Bilogix. Focused on boosting operational effectiveness, Cambridge Therapeutics head John Klein has developed Bilogix’s next generation enterprise performance management (EPM) platform.
While there are various strategic approaches to EPM, one common approach involves utilizing an analytical framework while working to provide predictive capabilities. Through intuitive scorecards and dashboards, executives are able to view a variety of metrics across several business units that are arranged at various hierarchical levels.
Adhering to rigorous six sigma processes, EPM applications effectively contextualize operational strategy through key performance indicators that quantify results in terms of attaining targets. This approach allows organizational processes to be aligned across functions, with resources actively deployed in areas that will bring about sought after change and transformation.
Within an integrated EPM framework, steps taken to improve the corporate process are disseminated via financial consolidation and management reporting.
John Klein is a pharmaceutical executive who has served as chairman of Cambridge Therapeutics in Alpine, NJ, since 2011. Beyond being responsible for establishing the strategic direction of the company, John Klein concurrently serves as chairman and CEO of the enterprise performance management (EPM) firm Bi-Logix, LLC.
EPM involves processes designed to boost business performance and has applications across a diverse range of industries. While it is useful and effective in reporting results to stakeholders, analyzing performance, and facilitating financial consolidation, it can have a particularly strong impact in regard to financial planning. Compared to manual methods of approaching finance such as spreadsheets, cloud-based EPM software is more automated and significantly less time-consuming. It also minimizes manual errors that might occur with the use of spreadsheets.
Another primary benefit of EPM software is the ability to integrate dynamic planning techniques such as rolling forecasts. This is particularly useful for businesses in rapidly-changing industries, as it lessens the reliance on making decisions based upon static assumptions via annual budgets. In contrast, a rolling forecast can be updated regularly to reflect business or industry changes.
John Klein draws upon more than four decades of leadership experience in the pharmaceutical sector to his position as chairman of the Alpine, NJ-based Cambridge Therapeutics. In addition to this role, John Klein serves as the chairman and CEO of Bilogix, LLC, which provides unique enterprise performance management (EPM) solutions to customers in line with their corporate strategy.
EPM services can enhance business strategy and processes such as budgeting and financial modeling and analysis. EPM is a complex methodology that involves a number of aspects, such as the creation of an enterprise strategy. Designed to help companies seeking to improve their performance, EPM requires a solid strategic plan as its basis. Through EPM, the various aspects of the strategic plan are deployed throughout an organization. Another area of EPM entails mapping an organization. A blueprint is created outlining how the work will be accomplished and what the outputs will be.
Mapping an organization aids in the identification of areas in need of improvement and key performance indicators (KPIs). An additional aspect of EPM involves developing scorecards. Business scorecards can provide managers with quick access to critical information. The scorecards show metrics on KPIs that can aid in managerial decision-making.
Possessing more than two decades of experience in pharmaceutical manufacturing, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. Aside from steering Cambridge Therapeutics, John Klein directs the business-development firm Bilogix.
Providing services in the growing field of enterprise performance management (EPM), Bilogix employs experienced consultants who assist businesses in conducting strategic analyses of their business intelligence (BI) and overall operational efficiency to perform better in a constantly-evolving marketplace.
EPM consultants might also evaluate the company’s expenditures and how much value that spending contributes to or review return on investment (ROI) data. The ROI process provides measurable values for determining an investment’s efficiency or making comparisons between different ones. Additionally, it assesses the return on specific investments in relation to its cost. These practices help to better inform executive management on how to create the best solutions for increasing performance and generating more profit for the enterprise.
A prominent pharmaceutical-industry executive based in Alpine, NJ, John Klein serves as the chairman of Cambridge Therapeutics. Previously named on Forbes’ list of the Top 100 CEOs, Cambridge Therapeutics’ John Klein has also led the Alpine, NJ-based business-consulting firm Bilogix since 2015.
An enterprise performance management (EPM) firm, Bilogix aims to serve as a strategic partner to businesses that wish to improve their future outlook in the midst of a rapidly-changing technological landscape. With more enterprises investing in digital solutions for everything from data storage and sales reports to customer relationship management, EPM consultants can help ensure an organization has a well-thought-out strategy for digital transformation.
Industry professionals advise chief executive officers to not hesitate too long before looking into EPM-driven technology solutions. A study by SAP and Oxford Economics found that 80 percent of companies had a rise in profitability after they completed a digital transformation. Those that fail to craft innovative business models and a comprehensive technological strategy that includes steps for integrating sales with the internet of things (IoT) will be left behind by their competition. However, trained EPM consultants can help companies ensure outstanding customer experiences as they continue to add increased technological capability.
An accomplished pharmaceutical industry executive, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to directing the business development of Cambridge Therapeutics, John Klein recently founded a new venture in the emerging field of enterprise performance management (EPM).
Based in Alpine, NJ, the newest company is called Bilogix. A provider of strategic consulting services to a range of companies and organizations, Bilogix draws on the business-development and technological expertise of its team to help enterprises enhance their information technology (IT) infrastructure and achieve maximum operational efficiency.
The highly complex field of EPM encompasses many aspects, such as visualization of business strategy and metrics using tools such as strategy maps and performance dashboards. In the area of budgeting, EPM authorities use a range of resources to support financial analysis and decision-making, including cost and profitability modeling tools and improved management reporting systems. Another overarching EPM-solution approach is the integrated performance management system, which gives executives the feedback they need to evolve as productive and effective professionals.